Cocrystal’s Says Lead COVID-19 Antiviral CDI-45205 Shown To Be Active Against SARS-CoV-2 And 2 Prominent SARS-CoV-2 Variants
Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the